Nutraceutical ingredient maker known globally for myHMB, a branded muscle-health supplement ingredient sold to supplement brands.
Nutraceutical ingredient maker known globally for myHMB, a branded muscle-health supplement ingredient sold to supplement brands.
Sells its HMB ingredient, a muscle-health compound, to supplement brands that put it in their own products, so revenue follows brand customers' reorders and the standing of the myHMB name, which is backed by published studies. It is an ingredient supplier, not a consumer brand.
In one line: A Chinese-owned global sports-nutrition ingredient supplier.
Moat: narrow (brand, IP / patents). Patented branded ingredient with clinical research backing gives pricing power over generic HMB.
Headquarters: Shanghai, China · Employees: 829
Size TSI (603262.SS) is a China Health Care company (Pharmaceuticals: Other) with a market value of $842M, the 2490th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.19 on 18 Nov 2026.
Performance Over six months the shares fell 45.8%, against -18.4% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 3.1% over the last twelve months (peer median +3.5%); the operating margin is 13.6% (peer median 12.6%).
Valuation It trades at 47.7× forward earnings against a peer median of 20.0× (3rd most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.8 points above its cost of capital (10.2% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2021 | FY2020 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.09B | CN¥1.09B | CN¥999M | CN¥801M | CN¥746M |
| Revenue growth | — | +9% | +25% | +7% | — |
| Gross profit | CN¥504M | CN¥445M | CN¥419M | CN¥292M | CN¥281M |
| EBITDA | n/a | CN¥192M | CN¥238M | CN¥171M | CN¥101M |
| Net income | CN¥116M | CN¥134M | CN¥174M | CN¥110M | CN¥46.8M |
| Free cash flow | CN¥20.5M | -CN¥30.0M | CN¥122M | CN¥22.3M | CN¥77.3M |
| Capital expenditure | CN¥218M | CN¥182M | CN¥105M | CN¥90.6M | CN¥47.1M |
| Total debt | CN¥76.3M | CN¥85.0M | CN¥75.3M | CN¥225M | CN¥227M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| TSI 603262.SS | $842M | -46% | +3% | 14% | 47.7× | 24.3% |
| Lonza LONN.SW | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% |
| Kyowa Kirin 4151.T | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603262.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.6% | -7.3% | 3rd lowest of 21 |
| 6-month return | -45.8% | -18.4% | lowest of 21 |
| Distance from 52-week high | -55.2% | -39.3% | 2nd lowest of 21 |
| Revenue growth (TTM) | +3.1% | +3.5% | 11th highest of 21 |
| Operating margin | 13.6% | 12.6% | 11th highest of 21 |
| Forward P/E | 47.7× | 20.0× | 3rd most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 24.3% | 4.4% | 2nd most demanding of 15 |
| Growth delivered (Del g) | +13.4% | +14.5% | 7th lowest of 15 |
| Hurdle (Req g minus delivered) | +11.0 pp | -8.7 pp | 2nd most demanding of 15 |
| ROIC minus cost of capital | +4.8 pp | +0.7 pp | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| TSI 603262.SS | China | $842M | -46% | +3% | 14% | 47.7× | 24.3% | +13.4% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $856M | -34% | +30% | 15% | 8.7× | n/a | n/a |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 33.5× | 4.7% | +18.5% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $760M | -8% | -18% | 25% | 7.6× | n/a | n/a |
| Sirio Pharma 300791.SZ | China | $759M | -6% | -9% | 1% | 16.2× | 14.1% | +15.6% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $942M | -18% | -14% | 8% | 182.0× | n/a | n/a |
| Applied Nutrition APN.L | United Kingdom | $986M | +31% | +51% | 25% | 21.4× | 24.6% | +38.5% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $718M | -36% | -12% | 3% | n/a | 2.1% | -1.3% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $703M | -20% | -14% | 22% | n/a | 0.4% | +4.8% |
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.01B | -17% | -5% | 4% | 20.0× | 0.5% | +7.9% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.05B | -12% | -3% | 24% | 12.8× | -8.7% | +5.5% |
| Brother Enterprises 002562.SZ | China | $668M | -33% | +8% | 4% | n/a | 4.0% | +13.5% |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $641M | -22% | -28% | -25% | n/a | n/a | n/a |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 11.7× | 13.1% | +62.3% |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $613M | -30% | 0% | 0% | n/a | n/a | n/a |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |
| ABA Chemicals 300261.SZ | China | $592M | -26% | -16% | -23% | 405.0× | n/a | n/a |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 41.4× | 10.6% | -3.9% |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $583M | -23% | +21% | 11% | 45.4× | 19.1% | +12.1% |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 31.0× | 1.5% | +15.5% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% | +60.2% |